| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Toronto, Canada M5G 1X5,1 University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, Canada M5G 2M9,2 Department of Physiology, University of Toronto, Medical Sciences Building, 1 King's College Circle, Toronto, Canada M5S 1A83
Received 15 November 2006/ Returned for modification 16 January 2007/ Accepted 11 April 2007
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Increasing evidence indicates that RNA splicing factors are actively involved in gene transcription through interaction with transcriptional factors and/or the core general transcriptional machinery (5, 65). RNA splicing factors influence transcription through the direct association with the carboxyl-terminal domain (CTD) of the largest subunit of eukaryotic polymerase II (Pol II) directly (15, 53). Splicing factors such as PGC-1, CoAA, and CAPER coactivate the transcriptional activity of nuclear receptors (2, 12, 43). The RNA splicing factors, PSF and p54nrb, share 71% identity within a central region that includes two RNA recognition motifs (RRMs). These factors can interact either directly (or indirectly through N-WASP) with the CTD of Pol II to facilitate the assembly of splicing complexes on the nascent RNA, thereby resulting in the stimulation of splicing and downstream RNA processing (53, 63). We have demonstrated that PSF corepresses several nuclear receptors including the progesterone receptor (PR) and the AR (11). PSF binds directly with DNA sequences containing an insulin-like growth factor response element in the p450 gene and represses its transcription (61). PSF and p54nrb have also been reported to inhibit transcription by recruiting HDACs through mSin3A to other nuclear receptors including steroidogenic factor 1, thyroid hormone receptors, and retinoid X receptors (41, 56). The mechanisms underlying these actions are unclear.
In addition to transcriptional modulation, PSF and p54nrb form multiple protein complexes. These different complexes perform several nuclear processes including pre-mRNA processing, nuclear retention of edited RNA, and DNA relaxation (58). In this study, we investigated the regulation of AR transactivation by PSF and p54nrb. We demonstrated that PSF and p54nrb interact with AR in a ligand-independent manner and corepress AR transactivation in several cell and promoter contexts, including the well-defined native AR target gene, prostate-specific antigen (PSA). Both PSF and p54nrb interact directly with mSin3A and mediate AR transactivation repression through recruitment of the HDAC complex. These findings indicate that in addition to their roles in facilitating RNA splicing, PSF and p54nrb function as corepressors of AR.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell culture and transfection. 293T and 293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM), and PC-3 and LNCaP cells were maintained in RPMI 1640 medium plus 10% fetal calf serum, as described previously (10, 32). For experiments involving steroid exposure, the medium was replaced with phenol red-free medium containing 10% charcoal-treated fetal bovine serum (HyClone). 293T or 293 cells were transfected with Exgen500 (MBI), while PC-3 and LNCaP cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Cells were transfected 24 h before the addition of dihydrotestosterone (DHT) and/or sodium butyrate (NaBu) for 24 h. Luciferase (Luc) assays were performed using a Promega Luciferase Kit according to the manufacturer's instruction.
Coimmunoprecipitation and Western blotting. For immunoprecipitation, 293T cells were transfected with a total of 10 µg of expression vectors in 100-mm culture dishes. Cells were lysed in TNET buffer (50 mM Tris 7.4, 150 mM NaCl, 1 mM EDTA, and 1% Triton) plus protease inhibitor cocktail. Cell lysates precleared with 5 µg of rabbit immunoglobulin G (IgG; Sigma) were incubated with specific antibodies overnight at 4°C, followed by the addition of 30 µl of protein A/G for another 2 h at 4°C. Resins were washed with TNET buffer and eluted with 1x Laemmli buffer, boiled, and centrifuged. The supernatant was separated by sodium dodecyl sulfate-8% polyacrylamide gel electrophoresis (SDS-8% PAGE), transferred to polyvinylidene difluoride membrane, and blotted by specific antibodies.
For immunoprecipitation of the endogenous AR, PSF, and p54nrb, LNCaP cells cultured in 150-mm dishes were lysed in TNET buffer. Cell lysates were then incubated with 5 µg of either AR antibody or rabbit IgG at 4°C overnight, followed by the addition of 30 µl of protein A/G Plus-agarose beads (Santa Cruz) for another 2 h at 4°C. Resins were washed with TNET buffer containing 250 mM NaCl and eluted with 1x Laemmli buffer. The eluted proteins along with the whole-cell extract were Western blotted by AR-, PSF-, and p54nrb-specific antibodies. Antibodies used were as follows: AR (N-20) and His tag (H-15) from Santa Cruz Biotechnology, PSF (B92) and Flag (M2) from Sigma, and p54nrb from BD Transduction Labs.
GST pull-down assay. A GST pull-down assay was performed as previously described (10). mSin3A was expressed in vitro using a TNT T7-coupled reticulocyte lysate system (Promega) with pSG5-mSin3A as the DNA template. The reticulocyte lysate containing [35S]methionine-labeled protein was incubated with GST and its fusion proteins. Associated proteins were recovered in SDS sample buffer and separated on SDS-PAGE gels. Gels were treated with Enhancer (NEN), dried, and analyzed by autoradiography.
Construction of siRNA vector. An internet-based program (Ambion Inc.) was used to design small interfering RNAs (siRNAs). Oligonucleotide DNA sequences based on these targeting sequences were synthesized and were engineered to possess BamHI- and HindIII-compatible overhangs and ligated to pSilencer 2.0 vector (Ambion Inc.). The target sequence used for human PSF (accession no. NM_005066) was 5'-AACTTACACACAGCGATGTCG-3' and the control scrambled sequence was 5'-AAATTACACATAGCGATGGCG-3'. Both vectors, siPSF and scrPSF, respectively, were confirmed by nucleotide sequencing.
ChIP and re-ChIP assays. Chromatin immunoprecipitation and reimmunoprecipitation (ChIP and re-ChIP) assays were performed with modifications of a previously described by procedure (17, 57). In brief, LNCaP cells were grown in phenol red-free RPMI 1640 medium with 10% charcoal-stripped fetal calf serum for 2 days before exposure to DHT. Chromatin was cross-linked with 1% formaldehyde for 10 min at 37°C and sonicated in lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris, pH 8.0, plus protease inhibitor cocktail). After centrifugation, 10 µl of the supernatants was used as input, and the remaining lysate was subjected to a ChIP assay. In re-ChIP assays, complexes were eluted by incubation in re-ChIP buffer (0.5 mM dithiothreitol, 1% Triton, 2 mM EDTA, 150 mM NaCl, and 20 mM Tris, pH 8.0) for 30 min and subjected again to a ChIP assay. The primers used to amplify AREs were the following: ARE I, 5'-TCTGCCTTTGTCCCCTAGAT-3' and 5'-AACCTTCATTCCCCAGGACT-3'; ARE III, 5'-CCTCCCAGGTTCAAGTGATT-3' and 5'-GCCTGTAATCCCAGCACTTT-3'; ARE X, 5'-CTGTGCTTGGAGTTTACCTGA-3' and 5'-GCAGAGGTTGCAGTGAGCC-3'.
Gel shift assay.
Gel shift assays were performed as previously described (11). Flag-tagged AR, PSF, and p54nrb were purified from 293 cells stably transfected with expression vectors with 400 ng/ml G418 selection. The cell lysate was incubated with M2-Sepharose beads (Sigma) according to the manufacturer's protocol. Double-strand synthetic oligonucleotide probes containing a palindromic consensus ARE (5'-AGCTTAGAACACAGTGTTCTCTAGAG-3') were labeled with [
-32P]ATP. Binding reactions were performed in a total volume of 20 µl in 1x reaction buffer [5% glycerol, 5 mM dithiothreitol, 5 mM EDTA, 250 mM KCl, 100 mM HEPES (pH 7.5), 1 µg of poly(dI-dC), 25 mM MgCl2, 1 mg/ml bovine serum albumin, 1 µg of salmon sperm DNA, 0.05% Triton X-100], 0.5 ng of labeled probe, 10 nM DHT, and purified proteins. The binding reaction was allowed to proceed for 20 min at room temperature (the supershift assay was performed by adding 1.5 to 5 µg of M2 antibody for an additional 45 min) before loading onto 5% nondenaturing polyacrylamide gels.
PSA analysis. Concentrations of PSA were determined by using an enzyme-linked immunosorbent assay (ELISA) with an Immulite 2500 PSA kit and the automatic immunometric analyzer Elecsys (Roche). Its detection limit is 0.005 ng/ml with a dynamic range up to 100 ng/ml. Briefly, culture medium was incubated with a biotinylated monoclonal PSA-specific antibody and a monoclonal PSA-specific antibody labeled with a ruthenium complex to form a sandwich complex. The complex was then bound to streptavidin-coated microparticles and captured onto the surface of the electrode. The unbound substances were removed with PreCell. Application of a voltage to the electrode induced a chemiluminescent emission, which was measured by a photomultiplier. Results were determined by a calibration curve, which was instrument-specifically generated by two-point calibration and a master curve provided via the reagent bar code. Other details for the ELISAs used have been described elsewhere (13, 32).
| RESULTS |
|---|
|
|
|---|
|
|
PSF inhibits AR transcriptional activity. Transient transfection reporter gene assays were conducted in several mammalian cell lines to determine the functional significance of PSF on AR transactivation. 293T human embryonic kidney cells and PC-3 human prostate cancer cells do not express endogenous AR, whereas LNCaP prostate cancer cells express an activated AR as a result of a point mutation [T877A, yielding AR(T877A)] in the ligand binding domain (LBD). We used two androgen-responsive promoters in these experiments: an artificial promoter with three copies of the ARE (3xARE) and the steroid-responsive mouse mammary tumor virus (MMTV) promoter. To control for possible adverse effects associated with overexpression of PSF cDNA, cells were also transfected with PSF-F. PSF-F shares the same amino acid sequences with PSF through amino acid residue 662, followed by a unique 9-amino-acid sequence at its C terminus. PSF-F localizes to the nuclear membrane within the cytoplasm, whereas PSF immunostaining is restricted to the cell nucleus in a punctate pattern (data not shown). In both 293T and PC-3 cells, overexpression of AR in the presence of 10 nM DHT resulted in a significant increase in Luc activity driven by the 3xARE and MMTV promoters (Fig. 3A). Cotransfection of PSF, but not PSF-F, decreased AR-induced Luc activity by up to 70%. PSF was also shown to inhibit transactivational activity of the mutant AR(T877A) in LNCaP cells (Fig. 3B). In addition, cotransfection of PSF with AR in 293T cells resulted in a dose-dependent inhibition of DHT-activated AR transactivation, but no inhibitory effects were observed in the absence of DHT (Fig. 3C). This inhibition was also observed over a wide range of DHT concentrations, from 0.1 nM to 1 µM (Fig. 3D).
|
p54nrb is a corepressor of AR. PSF has been demonstrated to heterodimerize with p54nrb, and our data indicate that p54nrb is found in AR/PSF complexes (Fig. 1). To characterize the functional effects of this interaction on AR transactivation, we transfected 293T and LNCaP cells with p54nrb and AR expression constructs and an MMTV-Luc reporter gene. Overexpression of p54nrb repressed AR activity in a dose-dependent fashion (Fig. 4A and B). To further confirm this inhibitory effect, we performed a mammalian one-hybrid assay, in which p54nrb cDNA was inserted into the pM vector to encode a fusion protein with the Gal4 DNA binding domain (DBD) at the N terminus of p54nrb (Fig. 4C). The pM-p54nrb was cotransfected with the reporter vector G5-Luc containing five Gal4 DBD response elements that are recognized by the fusion protein. Thus, the Luc activity reflects the impact of pM-p54nrb on transcriptional activity. We also constructed pM-PSF and pM-PR-B to serve as transcription-negative and -positive controls, respectively. Deletion mutations of PSF [PSF containing residues 150 to 707, 290 to 707, and 370 to 707, yielding PSF(150-707), PSF(290-707), and PSF(370-707), respectively] were included in this study, as the amino acid sequences of p54nrb are homologous to that of PSF(290-707). We observed that Gal4-dependent Luc activity mediated by pM-p54nrb was decreased compared to that obtained with the empty pM vector and was similar to that obtained with pM-PSF(290-707) (Fig. 4D). Furthermore, increasing doses of pM-p54nrb resulted in a proportional decrease of Luc activity (Fig. 4E). The expression levels of Gal4 DBD chimeras were confirmed by Western blotting of the transfected cell lysate with Gal4 DBD antibody (Fig. 4F and G). These data indicate that p54nrb possesses inhibitory function and represses AR-mediated transcription in different cell contexts.
|
|
-32P-labeled double-strand oligonucleotide containing a consensus ARE. One major migration-retarded band was observed, and its intensity increased proportionally to the AR protein input (Fig. 5E). The addition of 50- and 500-fold excess nonlabeled ARE resulted in disappearance of the retarded band, confirming the presence of ARE within the complex. M2 antibody induced the supershifted band, confirming the presence of AR within the complex. Addition of PSF but not p54nrb decreased this AR/ARE association. These data indicated that PSF but not p54nrb blocks AR binding to ARE in vitro. To further confirm that PSF impairs AR binding to ARE in vivo, we performed ChIP assays using LNCaP cells transiently transfected with mock (CMV-Flag, where CMV is cytomegalovirus; Sigma), Flag-PSF, or Flag-p54nrb expression vectors. The protein expression levels of AR, PSF, p54nrb were confirmed by immunoblotting with antibodies as indicated in Fig. 5F. In LNCaP cells transfected with mock vector, we detected robust recruitments of AR to both ARE I and III regions of the PSA gene after a 2-h treatment of DHT. Overexpression of PSF reduces the associations of AR with AREs, consistent with the gel shift assay evidence that PSF blocks AR binding to ARE. Interestingly, while p54nrb has no impact on AR binding to ARE in the in vitro gel shift assay, our ChIP assay indicated that overexpression of p54nrb also decreases the associations of AR to AREs. It could be that overexpression of p54nrb strengthens the association of PSF with AR (as we demonstrated by subsequent coimmunoprecipitation) (see Fig. 6D), thus blocking AR binding to ARE in the ChIP assay. Thus, we conclude from these data that both PSF and p54nrb block AR binding to ARE in vivo.
|
P54nrb mediates direct interaction with mSin3A and synergizes with PSF in repressing AR. Our data demonstrate that p54nrb represses transcriptional activity as determined by a one-hybrid assay and a steroid receptor-MMTV reporter system. However, it is not clear whether the repressor activity of p54nrb is mediated through direct interaction with mSin3A or indirectly through the formation of a protein complex with PSF. To address this, we performed a GST pull-down assay, in which immobilized GST, GST-p54nrb, or PSF was incubated with in vitro translated 35S-labeled mSin3A. We observed that both p54nrb and PSF interact directly with mSin3A (Fig. 6A). Furthermore, we showed that NaBu could reverse (i) p54nrb inhibition of Gal4 promoter activity (Fig. 6B) and (ii) p54nrb inhibition of AR-mediated MMTV promoter activity (Fig. 6C). Taken together, these data confirm that the repressor activity of p54nrb is mediated through direct binding to mSin3A and subsequent recruitment of HDAC to the complex. Immunoprecipitation analysis indicated that cotransfection of PSF and p54nrb resulted in considerably greater interaction with AR than that with either corepressor alone (Fig. 6D). Endogenously expressed mSin3A also exhibited a more intensive association with AR when both PSF and p54nrb were cotransfected. The functional consequences of this synergistic action were also explored by a one-hybrid assay and a steroid receptor-MMTV reporter system. Cotransfection of PSF and p54nrb resulted in a greater decrease of AR-mediated MMTV promoter activity than transfection of PSF or p54nrb alone (Fig. 6E). The repression effect of pM-PSF in the Gal4-responsive promoter was further enhanced by cotransfection with Flag-p54nrb; conversely, cotransfection of His-PSF induced a stronger inhibition by pM-p54nrb (Fig. 6F). However, the failure of His-PSF to further enhance repression by pM-PSF and of Flag-p54nrb to further enhance repression by pM-p54nrb argues against the formation of PSF or p54nrb homodimers. Finally, we showed that the repressor function of PSF and p54nrb is apparent in vivo. Stimulation of the prostate tumor cell line, LNCaP, with 10 nM DHT induced secretion of PSA, and this was inhibited by either PSF or p54nrb overexpression (Fig. 6G). Furthermore, as with the artificial promoter systems, the combination of PSF and p54nrb overexpression markedly enhanced this repression, consistent with the idea that PSF and p54nrb act as heterodimers. Thus, we conclude that the mechanisms by which p54nrb represses AR transactivation include (i) direct interaction with mSin3A/HDAC complexes and (ii) enhancement of the repressor activity of PSF.
PSF and p54nrb enhance the recruitments of mSin3A and HDAC1 to the PSA gene. In order to provide direct evidence that PSF and p54nrb recruit mSin3A and HDACs to the PSA gene, we performed a ChIP assay using LNCaP cells transfected with mock, Flag-PSF, or Flag-p54nrb expression vectors as shown in Fig. 5F. In mock-transfected LNCaP cells, we observed low but detectable levels of association of mSin3A and HDAC1 to both the ARE I and III regions of the PSA gene in the absence of DHT (Fig. 7). Treatment with DHT totally abolished these associations. Overexpression of either PSF or p54nrb enhanced the recruitment of mSin3A and HDAC1 to the AR-regulated promoter regions, providing evidence that these two splicing factors recruit the Sin3A/HDAC complex to AR complex on chromatin.
|
| DISCUSSION |
|---|
|
|
|---|
Our data indicate that PSF and p54nrb repress transactivation of AR through ligand-independent interactions, likely involving binding to the DBD of AR in a manner similar to that demonstrated for other nuclear receptors, such as PR and thyroid hormone receptors (11, 41). Our finding that PSF/p54nrb can repress transactivation of the mutant AR(T877A) (which changes the conformation of the LBD and broadens the specificity of ligand binding) further suggests that the LBD does not impact on PSF/p54nrb corepression of AR.
Our ChIP assay confirmed that the AR/PSF complex is present at both the ARE I and ARE III sites within the PSA gene. Overexpression of PSF and p54nrb enhanced the recruitment of the mSin3A/HDAC complex and, in turn, mediated histone deacetylation within the ARE I and III regions of the PSA gene. Our data suggest that the mechanism underlying the recruitment of the complexes to the AR is different from that of NCoR and SMRT. Thus, the recruitment of mSin3A/HDAC complex by NCoR and SMRT to the AR requires the presence of antagonist, whereas PSF/p54nrb can recruit this complex in a ligand-independent manner. Importantly, PSF occupies the ARE prior to detectable AR binding. Sin3A and HDACs have been reported to be recruited to chromatin in the absence of nuclear receptor ligand (35, 50). These observations suggest the existence of the mechanisms that prevent transcriptional leakage from the ligand-unbound AR, which is found within the nucleus (26, 30, 39).
Transcriptional activation of the PSA gene by AR involves a sequence of events including recruitment of AR and its coactivator complex to both ARE I and ARE III, thus bridging these two elements and inducing the looping of the promoter (62). Pol II is recruited in a sequential fashion, first to ARE III, then to the middle region, and finally to ARE I (62). Once transcription is initiated, Pol II moves along the gene, driving transcriptional elongation and cotranscriptional splicing. Our data suggest that in the absence of ligand, PSF occupies the AREs and forms protein complexes with mSin3A. This occupancy inhibits AR associations with both ARE I and III. In the presence of DHT, dissociation of PSF from ARE III permits AR/ARE III association and the initiation of gene transcription. The occupancy of PSF (a component of the spliceosome) on ARE I may facilitate the recruitment of the spliceosome complex to Pol II at the site of transcription initiation, enabling cotranscriptional splicing.
Our demonstration that p54nrb is a corepressor of AR contrasts with the previous report of Ishitami et al. (28). Our conclusion is based on the observations that (i) p54nrb interacts directly with mSin3A, (ii) p54nrb strengthens both the interaction with and corepression of AR by PSF, (iii) p54nrb represses transcription in multiple promoter contexts (MMTV, PSA, and Gal4 response promoter), (iv) the repressive effects of p54nrb can be reversed by the HDAC inhibitor NaBu, and (v) p54nrb blocks AR binding to AREs within the PSA gene in vivo. Furthermore, our own data (unpublished) as well as that of others (27, 56, 61) show that PSF/p54nrb can repress gene transcription mediated by other transcription factors. Nevertheless, PSF and p54nrb may also derepress gene transcription. Thus, cyclic AMP-induced dephosphorylation of PSF/p54nrb has been shown to result in the dissociation of these proteins from the mSin3A/HDAC complex (56). We speculate that phosphorylation of PSF and p54nrb may induce a conformational change in these proteins that modifies their corepressor activity. This possibility is currently under investigation in our laboratory.
Current models propose that transcription regulates splicing by controlling the rate of transcription and elongation; our data suggest that PSF/p54nrb may therefore impact transcriptional elongation. Slow elongation or an internal elongation pause favors the inclusion rather than the skipping of alternative exons (9, 31, 51). We hypothesize that PSF/p54nrb regulates the rate of transcription elongation through two possible mechanisms: (i) direct repression of AR-mediated gene transcription initiation and (ii) recruitment of the Sin3A/HDAC complex to deacetylate histones during transcription elongation. The observation that the inhibitor of histone deacetylation, trichostatin A, favors exon skipping (46) and that chromatin remodeling complex SWI/SNF regulates alternative splicing (4) supports the hypothesis that RNA splicing factors could recruit histone acetylase to modulate chromatin structure and, in turn, regulate the elongation rate and alternative splicing.
Dynamic exchange of coactivators and corepressors controls gene transcription and elongation. However, these processes must be coordinated with RNA processing to ensure smooth operation of the transcriptional machinery as it passes along the gene. The repressor activity of splicing factors such as PSF and p54nrb contributes to this smooth operation by slowing down both transcription initiation and elongation so that this can be coordinated with alternative splicing.
| ACKNOWLEDGMENTS |
|---|
This work was supported by an operating grant from the Canadian Institutes of Health Research (MOP-42378) and the Prostate Cancer Foundation of Canada.
| FOOTNOTES |
|---|
Published ahead of print on 23 April 2007. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Auboeuf, D., D. H. Dowhan, X. Li, K. Larkin, L. Ko, S. M. Berget, and B. W. O'Malley. 2004. CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing. Mol. Cell. Biol. 24:442-453.
3. Ayer, D. E., Q. A. Lawrence, and R. N. Eisenman. 1995. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80:767-776.[CrossRef][Medline]
4. Batsche, E., M. Yaniv, and C. Muchardt. 2006. The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat. Struct. Mol. Biol. 13:22-29.[CrossRef][Medline]
5. Bauren, G., and L. Wieslander. 1994. Splicing of Balbiani ring 1 gene pre-mRNA occurs simultaneously with transcription. Cell 76:183-192.[CrossRef][Medline]
6. Beato, M., P. Herrlich, and G. Schutz. 1995. Steroid hormone receptors: many actors in search of a plot. Cell 83:851-857.[CrossRef][Medline]
7. Bentley, D. 2002. The mRNA assembly line: transcription and processing machines in the same factory. Curr. Opin. Cell Biol. 14:336-342.[CrossRef][Medline]
8. Chen, J. D., and R. M. Evans. 1995. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457.[CrossRef][Medline]
9. de la Mata, M., C. R. Alonso, S. Kadener, J. P. Fededa, M. Blaustein, F. Pelisch, P. Cramer, D. Bentley, and A. R. Kornblihtt. 2003. A slow RNA polymerase II affects alternative splicing in vivo. Mol. Cell 12:525-532.[CrossRef][Medline]
10. Dong, X., J. R. Challis, and S. J. Lye. 2004. Intramolecular interactions between the AF3 domain and the C terminus of the human progesterone receptor are mediated through two LXXLL motifs. J. Mol. Endocrinol. 32:843-857.[Abstract]
11. Dong, X., O. Shylnova, J. R. Challis, and S. J. Lye. 2005. Identification and characterization of the protein-associated splicing factor as a negative co-regulator of the progesterone receptor. J. Biol. Chem. 280:13329-13340.
12. Dowhan, D. H., E. P. Hong, D. Auboeuf, A. P. Dennis, M. M. Wilson, S. M. Berget, and B. W. O'Malley. 2005. Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Mol. Cell 17:429-439.[CrossRef][Medline]
13. Ferguson, R. A., H. Yu, M. Kalyvas, S. Zammit, and E. P. Diamandis. 1996. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin. Chem. 42:675-684.
14. Fleischer, T. C., U. J. Yun, and D. E. Ayer. 2003. Identification and characterization of three new components of the mSin3A corepressor complex. Mol. Cell. Biol. 23:3456-3467.
15. Fong, N., and D. L. Bentley. 2001. Capping, splicing, and 3' processing are independently stimulated by RNA polymerase II: different functions for different segments of the CTD. Genes Dev. 15:1783-1795.
16. Fong, Y. W., and Q. Zhou. 2001. Stimulatory effect of splicing factors on transcriptional elongation. Nature 414:929-933.[CrossRef][Medline]
17. Gaughan, L., I. R. Logan, D. E. Neal, and C. N. Robson. 2005. Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res. 33:13-26.
18. Gelmann, E. P. 2002. Molecular biology of the androgen receptor. J. Clin. Oncol. 20:3001-3015.
19. Glass, C. K., and M. G. Rosenfeld. 2000. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:121-141.
20. Hassig, C. A., T. C. Fleischer, A. N. Billin, S. L. Schreiber, and D. E. Ayer. 1997. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89:341-347.[CrossRef][Medline]
21. Heinzel, T., R. M. Lavinsky, T. M. Mullen, M. Soderstrom, C. D. Laherty, J. Torchia, W. M. Yang, G. Brard, S. D. Ngo, J. R. Davie, E. Seto, R. N. Eisenman, D. W. Rose, C. K. Glass, and M. G. Rosenfeld. 1997. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48.[CrossRef][Medline]
22. Heisler, L. E., A. Evangelou, A. M. Lew, J. Trachtenberg, H. P. Elsholtz, and T. J. Brown. 1997. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol. Cell. Endocrinol. 126:59-73.[CrossRef][Medline]
23. Hodgson, M. C., I. Astapova, S. Cheng, L. J. Lee, M. C. Verhoeven, E. Choi, S. P. Balk, and A. N. Hollenberg. 2005. The androgen receptor recruits nuclear receptor corepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J. Biol. Chem. 280:6511-6519.
24. Horlein, A. J., A. M. Naar, T. Heinzel, J. Torchia, B. Gloss, R. Kurokawa, A. Ryan, Y. Kamei, M. Soderstrom, C. K. Glass, et al. 1995. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-404.[CrossRef][Medline]
25. Hu, X., and M. A. Lazar. 1999. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402:93-96.[CrossRef][Medline]
26. Huang, Z. Q., J. Li, and J. Wong. 2002. AR possesses an intrinsic hormone-independent transcriptional activity. Mol. Endocrinol. 16:924-937.
27. Iacobazzi, V., V. Infantino, P. Costanzo, P. Izzo, and F. Palmieri. 2005. Functional analysis of the promoter of the mitochondrial phosphate carrier human gene: identification of activator and repressor elements and their transcription factors. Biochem. J. 391:613-621.[CrossRef][Medline]
28. Ishitani, K., T. Yoshida, H. Kitagawa, H. Ohta, S. Nozawa, and S. Kato. 2003. p54nrb acts as a transcriptional coactivator for activation function 1 of the human androgen receptor. Biochem. Biophys. Res. Commun. 306:660-665.[CrossRef][Medline]
29. Jenster, G., T. E. Spencer, M. M. Burcin, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley. 1997. Steroid receptor induction of gene transcription: a two-step model. Proc. Natl. Acad. Sci. USA 94:7879-7884.
30. Jenster, G., J. Trapman, and A. O. Brinkmann. 1993. Nuclear import of the human androgen receptor. Biochem. J. 293:761-768.[Medline]
31. Keene, R. G., A. Mueller, R. Landick, and L. London. 1999. Transcriptional pause, arrest and termination sites for RNA polymerase II in mammalian N- and c-myc genes. Nucleic Acids Res. 27:3173-3182.
32. Kollara, A., E. P. Diamandis, and T. J. Brown. 2003. Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells. J. Steroid Biochem. Mol. Biol. 84:493-502.[Medline]
33. Laherty, C. D., A. N. Billin, R. M. Lavinsky, G. S. Yochum, A. C. Bush, J. M. Sun, T. M. Mullen, J. R. Davie, D. W. Rose, C. K. Glass, M. G. Rosenfeld, D. E. Ayer, and R. N. Eisenman. 1998. SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. Mol. Cell 2:33-42.[CrossRef][Medline]
34. Laherty, C. D., W. M. Yang, J. M. Sun, J. R. Davie, E. Seto, and R. N. Eisenman. 1997. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89:349-356.[CrossRef][Medline]
35. Li, J., Q. Lin, W. Wang, P. Wade, and J. Wong. 2002. Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes Dev. 16:687-692.
36. Liao, G., L. Y. Chen, A. Zhang, A. Godavarthy, F. Xia, J. C. Ghosh, H. Li, and J. D. Chen. 2003. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J. Biol. Chem. 278:5052-5061.
37. Lonard, D. M., and B. W. O'Malley. 2006. The expanding cosmos of nuclear receptor coactivators. Cell 125:411-414.[CrossRef][Medline]
38. Mangelsdorf, D. J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, and R. M. Evans. 1995. The nuclear receptor superfamily: the second decade. Cell 83:835-839.[CrossRef][Medline]
39. Marcelli, M., D. L. Stenoien, A. T. Szafran, S. Simeoni, I. U. Agoulnik, N. L. Weigel, T. Moran, I. Mikic, J. H. Price, and M. A. Mancini. 2006. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J. Cell Biochem. 98:770-788.[CrossRef][Medline]
40. Masuhiro, Y., Y. Mezaki, M. Sakari, K. Takeyama, T. Yoshida, K. Inoue, J. Yanagisawa, S. Hanazawa, W. O'Malley, B., and S. Kato. 2005. Splicing potentiation by growth factor signals via estrogen receptor phosphorylation. Proc. Natl. Acad. Sci. USA 102:8126-8131.
41. Mathur, M., P. W. Tucker, and H. H. Samuels. 2001. PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptors. Mol. Cell. Biol. 21:2298-2311.
42. McKenna, N. J., and B. W. O'Malley. 2002. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465-474.[CrossRef][Medline]
43. Monsalve, M., Z. Wu, G. Adelmant, P. Puigserver, M. Fan, and B. M. Spiegelman. 2000. Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Mol. Cell 6:307-316.[CrossRef][Medline]
44. Neugebauer, K. M. 2002. On the importance of being co-transcriptional. J. Cell Sci. 115:3865-3871.
45. Ni, Z., B. E. Schwartz, J. Werner, J. R. Suarez, and J. T. Lis. 2004. Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes. Mol. Cell 13:55-65.[CrossRef][Medline]
46. Nogues, G., S. Kadener, P. Cramer, D. Bentley, and A. R. Kornblihtt. 2002. Transcriptional activators differ in their abilities to control alternative splicing. J. Biol. Chem. 277:43110-43114.
47. Ordentlich, P., M. Downes, W. Xie, A. Genin, N. B. Spinner, and R. M. Evans. 1999. Unique forms of human and mouse nuclear receptor corepressor SMRT. Proc. Natl. Acad. Sci. USA 96:2639-2644.
48. Park, E. J., D. J. Schroen, M. Yang, H. Li, L. Li, and J. D. Chen. 1999. SMRTe, a silencing mediator for retinoid and thyroid hormone receptors-extended isoform that is more related to the nuclear receptor corepressor. Proc. Natl. Acad. Sci. USA 96:3519-3524.
49. Price, D. H. 2000. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol. 20:2629-2634.
50. Qiu, Y., Y. Zhao, M. Becker, S. John, B. S. Parekh, S. Huang, A. Hendarwanto, E. D. Martinez, Y. Chen, H. Lu, N. L. Adkins, D. A. Stavreva, M. Wiench, P. T. Georgel, R. L. Schiltz, and G. L. Hager. 2006. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol. Cell 22:669-679.[CrossRef][Medline]
51. Roberts, G. C., C. Gooding, H. Y. Mak, N. J. Proudfoot, and C. W. Smith. 1998. Co-transcriptional commitment to alternative splice site selection. Nucleic Acids Res. 26:5568-5572.
52. Rosenfeld, M. G., V. V. Lunyak, and C. K. Glass. 2006. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20:1405-1428.
53. Rosonina, E., J. Y. Ip, J. A. Calarco, M. A. Bakowski, A. Emili, S. McCracken, P. Tucker, C. J. Ingles, and B. J. Blencowe. 2005. Role for PSF in mediating transcriptional activator-dependent stimulation of pre-mRNA processing in vivo. Mol. Cell. Biol. 25:6734-6746.
54. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
55. Schreiber-Agus, N., L. Chin, K. Chen, R. Torres, G. Rao, P. Guida, A. I. Skoultchi, and R. A. DePinho. 1995. An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80:777-786.[CrossRef][Medline]
56. Sewer, M. B., V. Q. Nguyen, C. J. Huang, P. W. Tucker, N. Kagawa, and M. R. Waterman. 2002. Transcriptional activation of human CYP17 in H295R adrenocortical cells depends on complex formation among p54(nrb)/NonO, protein-associated splicing factor, and SF-1, a complex that also participates in repression of transcription. Endocrinology 143:1280-1290.
57. Shang, Y., M. Myers, and M. Brown. 2002. Formation of the androgen receptor transcription complex. Mol. Cell 9:601-610.[CrossRef][Medline]
58. Shav-Tal, Y., and D. Zipori. 2002. PSF and p54(nrb)/NonOmulti-functional nuclear proteins. FEBS Lett. 531:109-114.[CrossRef][Medline]
59. Shiio, Y., D. W. Rose, R. Aur, S. Donohoe, R. Aebersold, and R. N. Eisenman. 2006. Identification and characterization of SAP25, a novel component of the mSin3 corepressor complex. Mol. Cell. Biol. 26:1386-1397.
60. Tsai, M. J., and B. W. O'Malley. 1994. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63:451-486.[CrossRef][Medline]
61. Urban, R. J., Y. Bodenburg, A. Kurosky, T. G. Wood, and S. Gasic. 2000. Polypyrimidine tract-binding protein-associated splicing factor is a negative regulator of transcriptional activity of the porcine p450scc insulin-like growth factor response element. Mol. Endocrinol. 14:774-782.
62. Wang, Q., J. S. Carroll, and M. Brown. 2005. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol. Cell 19:631-642.[CrossRef][Medline]
63. Wu, X., Y. Yoo, N. N. Okuhama, P. W. Tucker, G. Liu, and J. L. Guan. 2006. Regulation of RNA-polymerase-II-dependent transcription by N-WASP and its nuclear-binding partners. Nat. Cell Biol. 8:756-763.[CrossRef][Medline]
64. Zeng, C., and S. M. Berget. 2000. Participation of the C-terminal domain of RNA polymerase II in exon definition during pre-mRNA splicing. Mol. Cell. Biol. 20:8290-8301.
65. Zhang, G., K. L. Taneja, R. H. Singer, and M. R. Green. 1994. Localization of pre-mRNA splicing in mammalian nuclei. Nature 372:809-812.[Medline]
66. Zhang, Y., R. Iratni, H. Erdjument-Bromage, P. Tempst, and D. Reinberg. 1997. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell 89:357-364.[CrossRef][Medline]
67. Zhang, Y., Z. W. Sun, R. Iratni, H. Erdjument-Bromage, P. Tempst, M. Hampsey, and D. Reinberg. 1998. SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex. Mol. Cell 1:1021-1031.[CrossRef][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||